

The role of *kras* mutations and MSI status in diagnosis of colorectal cancer

Atena Irani Shemirani, Mahdi Montazer Haghighi, Saman Milanizadeh, Mohammad Yaghoob Taleghani, Seyed Reza Fatemi, Behzad Damavand, Zahra Akbari, Mohammad Reza Zali

Research Institute for Gastroenterology and Liver Disease, Shahid Beheshti University of Medical Sciences, Tehran, Iran

ABSTRACT

Aim: The aim of the current investigation was to examine the profile of *Kras* mutations accompanied with MSI (microsatellite instability) status in polyps and colorectal carcinoma tissues in an Iranian population.

Background: *Kras* mutations in colorectal cancer cause resistance to anti-Epidermal Growth Factor Receptor (EGFR). So it can be considered as a true indicator of EGFR pathway activation status. *Kras* mutations can be detected in approximately 30% to 40% of all patients with colorectal cancer. The most hot spot of the gene is located in exons 2 and 3.

Patients and methods: In this study we examined exons 2 and 3 *Kras* gene using polymerase chain reactions and subsequent sequencing of the exons in 95 patients with sporadic colorectal cancer including 48 tumors and 47 polyps. This study was performed using biopsy samples from the patients. We sequenced the *Kras* gene in a panel of human colorectal tumors and polyps in addition to detecting MSI status using fluorescent technique.

Results: We could detect 6 mutations in tumors including 5 mutations in codon 12 and one mutation in codon 13. Moreover, in polyps 2 mutations were determined in codon 13 and one in codon 12. Microsatellite instability assay revealed the presence of 5 and 6 MSI in tumors and polyps, respectively. Among the MSI mononucleotide markers, NR-21 marker demonstrated the most frequency (60%) in the both groups.

Conclusion: Our findings showed that probably the profile of mutations in tumors is not entirely compatible with the pattern of mutations in polyps. However, just one of the mutations, Gly12Asp, was similar in both groups.

Keywords: *Kras*, Colorectal cancer, Mutation, MSI, Tumor, Polyp.

(Gastroenterology and Hepatology From Bed to Bench 2011;4(2):70-75).

Introduction

The development of colorectal cancer (CRC) is a multi-step process characterized by the accumulation of genetic alterations (1). The evolution of colorectal cancer from polyps was first proposed by Morson (2). Since the seminal publication of Vogelstein and Fearon (3), we understand that most colorectal cancers arise in a multistep process progressing from mucosal hyperplasia to adenomas and carcinomas.

The transformation of normal colonic epithelium to cancer is a multi-step process which is characterized by activating oncogenes and inactivating tumor suppressor genes. *Kras* (Kirsten rat sarcoma viral oncogene homologue) is a small GTPase (guanosin triphosphate cleaving enzyme) involved in intracellular signal transduction. It is a member of MAP kinase (MAPK) pathway (4). *Kras* mutations lead to the deregulation of *Kras* protein activity, which results in the loss of GTPase activity and gain of oncogenic activity (5). Specific mutations in the *Kras* gene leads to the formation of constitutively

Received: 22 July 2010 Accepted: 19 December 2010

Reprint or Correspondence: Mahdi Montazer Haghighi, PhD. Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University, M.C., Iran

E-mail: mah_haghighi@hotmail.com

Table 1. Specific primers for exon 2 and 3

Name	Gene	Primer Sequence	Tm	Size
F-exon2	<i>Kras</i>	5'-GACCCTGACATACTCCCAAG-3'	63	493
R-exon2	<i>Kras</i>	5'-TACAGTTCATTACGATACACG-3'	63	494
F-exon3	<i>Kras</i>	5'-GACTGTGTTTCTCCCTTCTC-3'	59	402
R-exon3	<i>Kras</i>	5'-TTTCAATCCCAGCACCACCAC-3'	59	402

active protein, which triggers the transduction of proliferative and/or differentiative signals, even in the absence of extracellular stimuli (6). Mutations in the *Kras* gene which are responsible for malignant transformation are point mutations in exons 2 and 3. *Kras* mutations are observed in approximately 37.4% of the Iranian patients with colorectal cancer.

Mutations in the *Kras* gene contribute at an early stage to the development in the colon tumorigenesis pathway (7). *Kras* mutations occur in both microsatellite instable (MSI) in about 20% and Microsatellite stability (MSS) in about 35% subsets of sporadic CRC (8, 9). There have been approximately 3000 *kras* point mutations in colorectal cancer reported in the literature (10). According to a previous study in Iran, most mutations were in codons 12 and 13 therefore, these codons were examined. This confirms that codons 12 and 13 are preferentially involved in Iranian population as well (7).

The aim of the study was to evaluate point mutations in exon 2 and 3 *Kras* gene in 95 carcinomas and polyps samples, furthered by the comparison of mutations profile in the polyp and tumor samples. Moreover, the MSI status in both groups was examined. Finding the probable mutation and most frequent MSI marker will be useful for early detection of sporadic colorectal cancer.

Patients and Methods

This investigation was a case series study. Samples of cancer and polyps tissues were collected from 95 patients with sporadic colorectal cancers who underwent colonoscopy in Taleghani hospital Tehran from June 2008 to December 2009. The colonoscopy results were confirmed by

pathological examinations. Patients with FAP and HNPCC or individuals with familial background were excluded. The use of patient samples was approved by the local ethics committee at Research Center for Gastroenterology and Liver Disease. The patient panel was comprised of 73 men and 22 women, age ranging from 13 to 85 years with a median 49 years. Samples were taken immediately after resection and placed in liquid nitrogen. Genomic DNA was obtained from all colorectal fresh tissue using QiaGen kit. Patients characteristics are presented in table 1. The 493 bp region in the exon 2 and 402 bp in exon 3 of *Kras* gene that encompasses the mutation hotspots were amplified by PCR using specific forward and reverse primer, and Taq DNA polymerase (Table 1, Figure 1, 2).

The PCR was conducted with denaturing step at 94 °C for 5 min, then 30 sec at 94 °C, 30 sec at 56/63 °C and 30 sec at 72 °C for 30 cycles, followed by a final 5 min at 72 °C. The PCR products were then subjected to direct sequencing using the same primers, and all mutations were confirmed by sequence originating from both the upstream and downstream primers.




Figure 1. PCR-product related to exon2




Figure 2. PCR-product related to exon3

Direct sequencing was performed using fluorescent dideoxy on ABI sequencing 3130 XL according to manufacturer instructions. Samples were then subjected to direct sequencing of single-strand PCR product using the Big Dye Terminator v1.1 cycle sequencing kit and the ABI Prism 3130XL genetic analyzer (Applied Biosystems). All products were sequenced bidirectionally. The electropherograms were processed using Lasergene software version 6 (DNA star). Microsatellite analysis using fluorescence labeled

primers and automated DNA sequencer (ABI 3130XL Applied Biosystems, Foster City, CA, USA) were performed. Five human mononucleotide microsatellite, NR-24, NR-21, NR-27, BAT-25 and BAT-26 were used as the markers (11).

Microsatellite analysis using five fluorescent-labeled primers were performed according to following PCR condition, 94 °C for 5 min, then 30 sec at 94 °C, 40 sec at 55 °C and 30 sec at 72 °C for 35 cycles, followed by a final 7 min at 72 °C and automated DNA sequencer. Analysis of MSI status was based on multiplex amplification of the 5 quasimonomorphic mononucleotide repeat microsatellite (11). As a result of Microsatellite instability, MSI was considered when one or more than one marker was altered but in MSS no marker was changed.

Results

Kras mutations in exons 2 and 3 were evaluated in 95 patients with colorectal cancer including 47 polyps and 48 tumors.

In polyp samples three (6.4%) mutations were

Table 2. Characteristics of samples with mutation

Patient No.	Sex	Age	Location	Pathology results	Mutation	MSI- result
3T	F	43	colon	Adenocarcinoma	c.35 G>A, p.Gly12 Asp	MSI-L (NR-21)
26T	F	57	colon	Adenocarcinoma	c.38 G>A, p.Gly12 Asp	MSS
40T	F	51	colon	Adenocarcinoma	c.35 G>A, p.Gly12 Asp	MSI-L (NR-21)
75T	F	58	colon	Adenocarcinoma	c.35G>A, p.Gly12 Asp	MSS
80T	M	80	rectum	Adenocarcinoma	c.35 G>A, p.Gly12 Cys	MSS
81T	F	56	colon	Adenocarcinoma	c.35 G>A, p.Gly12 Asp	MSS
124P	M	61	rectum	Adenoma	c.37 G>T, p.Gly13 Asp	MSI-L (NR-25)
45P	F	43	colon	Adenoma	c.35 G>C, p.Gly13 Ala	MSS
57P	F	45	rectum	Adenoma	c.37 T>A, p.Gly12 Gly	MSS

MSI-L : MSI Low; MSS: MSI Stable; P= polyp; T=tumor

detected. The mutations were in codon 12 and 13. They were three different types of mutations, Gly13Ala, Gly13Gly and Gly12Asp. Furthermore, we detected the MSI status of all polyps using pentaplex set of microsatellite markers. Our finding showed 8 (17%) polyps samples with MSI and 39 (83%) samples with MSS (Table 2, 3).

Six out of 48 (12.5%) carcinoma specimens exhibited *Kras* mutation including five in codon 12 (Gly12Asp) and one in codon 13 (Gly13Cys). All of the *Kras* amino acid change in codon 12 was glycine to aspartic acid (G12A). Five out of six (83.4%) mutations occurred in females and just one (16.6%) of them happened in a male. MSI analysis revealed that 5 MSI (10.4%) and 43 (89.6%) MSS (Table 2, 3).

Table 3. MSI results related to tumor and polyp specimens

Patients No.	Type of Samples	MSI Results	Changed MSI marker
3	Tumor	MSI-L	(BAT-25)
6	Tumor	MSI-L	(NR-21)
8	Polyp	MSI-L	(NR-21)
10	Polyp	MSI-H	(NR-21), (NR-24)
24	Polyp	MSI-L	(BAT-25)
29	Polyp	MSI-L	(NR-21)
40	Tumor	MSI-L	(NR-21)
41	Tumor	MSI-L	(NR-24)
50	Polyp	MSI-L	(NR-24)
55	Polyp	MSI-L	(NR-21)
62	Polyp	MSI-L	(NR-21)
79	Tumor	MSI-L	(NR-21)
124	Polyp	MSI-L	(BAT-25)

Furthermore, we could detect 9 intronic mutations in 48 tumor samples including five int.2271A>C (55.6%), three int.2271C (33.3%) and one int.2271T>C (11.1%). While in 47 polyp samples 15 intronic mutations were found. They consist of, 13 int.2271A>C (86.7%) and two int.2271C. (13.3%) (Table 4).

Table 4. Profile of intronic mutations in polyp and tumor samples

Patients No.	Intronic Mutations	MSI assay
1T	Int.2271A>C	MSI-L (BAT-25)
3T	Int.2271A>C	MSS
12P	Int.2271A>C	MSS
22T	Int.2271A>C	MSS
32P	Int.2271A>C	MSS
39P	Int.2271A>C	MSS
41T	Int.2271A>C	MSI-L (NR-24)
42P	Int.2271A>C	MSS
46P	Int.2271A>C	MSS
48P	Int.2271A>C	MSS
49P	Int.2271A>C	MSS
52P	Int.2271A>C	MSS
54P	Int.2271C	MSS
58P	Int.2271C	MSS
60P	Int.2271A>C	MSS
62P	Int.2271A>C	MSI-L(NR-21)
64T	Int.2271C	MSS
66P	Int.2271A>C	MSS
69P	Int.2271A>C	MSS
72T	Int.2271T>C	MSS
75T	Int.2271C	MSS
76T	Int.2271A>C	MSS
79T	Int.2271A>C	MSI-L(NR-21)
80T	Int.2271C	MSS

As table 2 shows location of 5 out of 6 tumors with *Kras* mutation were in colon and only one tumor was detected in rectum. In contrast, 2 out of 3 polyps with *Kras* mutation were located in rectum and just one of them was determined in colon.

Of the 6 tumors with *Kras* mutations, 5 (83%) were G to A (Gly12Asp) and one was (17%) G to C (Gly12Cys). The type of *Kras* mutation was investigated in each MSI status. The frequency of G to A transition mutations in MSI-L and MSS was identical but they were higher than in MSI-H cancer. There was not any significant correlation between polyps or tumors with mutation and individuals clinical features (data was not shown) (Table 2).

Discussion

Mutations in the *Kras* oncogene are thought to occur at an early stage in the adenoma-carcinoma sequence, with the frequency of mutations

increasing with the adenoma size in Western countries, with an age-adjusted incidence of 49 out of 100,000 per year. Colorectal cancer is one of the most frequent malignant human tumors however, in Iranian population CRC incidence rate is 6–7.9 per 100,000 persons/ year (7, 12-14). These reports reflect that such incidence is remarkably lower than the rates reported in Western countries. This study investigated the ratio of *Kras* exon 2 and 3 in adenoma and adenomcarcinoma tissues in order to compare the mutations in two types of samples.

Replacement of glycine 12 of *Kras* with any amino acid, except proline, causes the biochemical activation of *Kras* by the reduction of its intrinsic GTPase activity of *Kras* (15). Substitution of glycine 12 with proline renders *Kras* resistant to the catalysis of GAPs yet increases intrinsic GTPase activity, which is biologically significant in hydrolyzing GTP to GDP and reverting *Kras* back to its inactive form. This phenotype is not aggressive in nature (16).

Comparing the frequency of *Kras* mutations highlighted, it is found that the frequency of *Kras* mutations detected in polyps is not statistically different from the frequency observed in MSI and MSS colorectal tumors.

Various studies in colorectal cancer have suggested that *Kras* codon 12 and 13 mutations are generally predictive of a poorer prognosis, with evidence being presented for mutation-specific prognostic as well as histopathology correlates (13-16).

The most frequent of exonic mutation was related to Gly12Asp. It could be considered as a biomarker before chemotherapy and also to evaluate prognosis. We could find Gly12Asp is a common mutation in tumor and polyp samples.

The rate of mutation in intronic region in polyp samples was higher than mutation rate in tumor samples. Therefore it is confirmed that these regions probably are not located in

alternative splicing of the *kras* gene. Five of the 6 mutations that were identified in tumor samples were missense and led to the substitution of glycine to aspartate.

Our finding in respect of the most frequent mutation, Gly12Asp, in the studied population is compatible with the results revealed from Italian population. However, it was in contrast with another study from Iranian population in a similar investigation (7).

These G → A transition mutations occurred in two ways - either by misreplication of the unrepaired endogenously produced O6-methylguanine DNA methyltransferase (MGMT) from faulty S-adenosylmethionine methylation or due to exposure to nitrosamines (17-19). In this respect other DNA repair systems, such as O6 methylguanine-DNA methyltransferase activity, are linked to the inability to protect from G to A transition in *Kras* induced by alkylating agents (20, 21). It has been suggested that other repair systems could also contribute to this repair mechanism (21). Further grouping of *Kras* mutations with regard to type and nucleotide position was shown to be significantly less frequent. The most frequent of MSI marker in this study was NR-21. In summary, we could consider mutation Gly12Asp in exon 2 as a biomarker to prediagnosis susceptible individuals before tumorigenesis. Nevertheless, how the *Kras* mutation may specifically modulate intracellular signaling is not well understood and remains a matter of ongoing research.

References

1. Lubomierski N, Plotz G, Wormek M, Engels K, Kriener S, Trojan J, et al. BRAF mutations in colorectal carcinoma suggest two entities of microsatellite-unstable tumors. *Cancer* 2005; 104: 952-61.
2. Morson B. The polyp-cancer sequence in the large bowel. *Proc R Soc Med* 1974; 67: 451-57.
3. Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M, et al. Genetic alterations

during colorectal-tumor development. *N Engl J Med* 1988; 319: 525–32.

4. Muller PAJ, Caswell PT, Doyle B, Iwanicki MP, Tan EH, Karim S, et al. Mutant p53 drives invasion by promoting integrin recycling. *Cell* 2009; 139: 1327–41.

5. Velho S, Moutinho C, Cirmes L, Albuquerque C, Hamelin R, Schmitt F, et al. BRAF, KRAS and PIK3CA mutations in colorectal serrated polyps and cancer: Primary or secondary genetic events in colorectal carcinogenesis? *BMC Cancer* 2008; 8: 255

6. Sameer AS, Chowdhri NA, Abdullah S, Shah ZA, Siddiqi MA. Mutation pattern of K-ras gene in colorectal cancer patients of Kashmir: a report. *Indian J Cancer* 2009; 46: 219-25.

7. Bishehsari F, Mahdavinia M, Malekzadeh R, Verginelli F, Catalano T, Sotoudeh M, et al. K-ras mutation in colorectal carcinomas from Iran and Italy (a Gruppo Oncologico dell'Italia Meridionale study): influence of microsatellite instability status and country of origin. *Ann Oncol* 2006; 17: vii91–vii96.

8. Oliveira C, Velho S, Moutinho C, Ferreira A, Preto A, Domingo E, et al. KRAS and BRAF oncogenic mutations in MSS colorectal carcinoma progression. *Oncogene* 2007; 26: 158-63.

9. Oliveira C, Westra JL, Arango D, Ollikainen M, Domingo E, Ferreira A, et al. Distinct patterns of KRAS mutations in colorectal carcinomas according to germline mismatch repair defects and hMLH1 methylation status. *Hum Mol Genet* 2004; 13: 2303-11.

10. Catalogue of somatic mutations in cancers. Available from: www.sanger.ac.uk/genetics/CGP/cosmic.

11. Buhard O, Suraweera N, Lectard A, Duval A, Hamelin R. Quasimonomorphic mononucleotide repeats for high-level microsatellite instability analysis. *Dis Markers* 2004; 20: 251-57.

12. Santini D, Loupakis F, Vincenzi B, Floriani I, Stasi I, Canestrari E, et al. High concordance of Kras

status between primary colorectal tumors and related metastatic sites: implications for clinical practice. *Oncologist* 2008; 13: 1270–75.

13. Zauber P, Sabbath-Solitare M, Marotta SP, Bishop DT. Molecular changes in the Ki-ras and APC genes in primary colorectal carcinoma and synchronous metastases compared with the findings in accompanying adenomas. *Mol Pathol* 2003; 56: 137–40.

14. Wickia A, Herrmannb R, Christoforic G. Kras in metastatic colorectal cancer. *Curr Opin* 19 November 2010.

15. Franken SM, Scheidig AJ, Krengel U, Rensland H, Lautwein A, Geyer M. Three-dimensional structures and properties of a transforming and a nontransforming glycine-12 mutant of p21H-ras. *Biochemistry* 1993; 32: 8411-20.

16. Stenson PD, Ball EV, Mort M, Phillips AD, Shiel JA, Thomas NS, et al. Human Gene Mutation Database (HGMD): 2003 update. *Hum Mutat* 2003; 21: 577-81.

17. Rydberg B, Lindahl T. Nonenzymatic methylation of DNA by the intracellular methyl group donor S-adenosyl-L-methionine is a potentially mutagenic reaction. *EMBO J* 1982; 1: 211-16.

18. Lijinsky W. N-Nitroso compounds in the diet. *Mutat Res* 1999; 443: 129-38.

19. Cole DN, Carlson JA, Wilson VL. Human germline and somatic cells have similar TP53 and Kirsten-RAS gene single base mutation frequencies. *Environ Mol Mutagen* 2008; 49: 417-25.

20. Calistri D, Rengucci C, Seymour I, Lattuneddu A, Polifemo AM, Monti F, et al. Mutation Analysis of p53, K-ras, and BRAF Genes in Colorectal Cancer Progression. *J Cell Physiol* 2005; 204:484-8.

21. Chiang JM, Wu Chou YH, Ma SC, Chen JR, et al. Influence of age on adenomatous polyposis coli and p53 mutation frequency in sporadic colorectal cancer-rarity of co-occurrence of mutations in APC, K-ras, and p53 genes. *Virchows Arch* 2004; 445: 465-71.